IRF8 and B-cell non-Hodgkin lymphoma: In murine B cell lymphoma models, which allow for in vitro (CD4 DO-11.10 cells) and in vivo functional examination of defective antigen presentation, CD74 appear to be the main “target” of IRF8 effects (Fig. 5, B to E).